Tirosint (Levothyroxine Sodium) Patent Expiration, LOE Window & CMS Spending

Tirosint (Levothyroxine Sodium) by Ibsa Institut Biochimique Sa: FDA Orange Book LOE 2044-09-26, 7 AB generics, $22.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIbsa Institut Biochimique Sa
FDA Application & PathwayN021924 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2044-09-26
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$22.8M
2024 Medicare Part D Spend$16.6M
2024 Medicaid Spend$6.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel